Cellbox Labs develops vascularized organ-on-chip technology that enables pharmaceutical companies to conduct preclinical drug tests using human-like micro-physiological systems. This platform combines hardware and software to facilitate flexible experimental designs while significantly reducing hands-on time in drug discovery processes.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical companies face challenges in accurately predicting drug efficacy and toxicity during preclinical testing due to the limitations of traditional cell culture and animal models. These models often fail to replicate the complexity of human physiology, leading to inaccurate results and costly late-stage drug failures.
Solution
Cellbox Labs provides a vascularized organ-on-chip platform that enables pharmaceutical companies to conduct more physiologically relevant preclinical drug tests. Their technology combines microfluidic hardware and software to create human-like microphysiological systems that mimic the structure and function of living tissues. This platform allows for flexible experimental designs and significantly reduces hands-on time, providing a more accurate and efficient way to assess drug candidates. By using these advanced in-vitro models, researchers can improve the prediction of drug responses in humans, leading to better drug development outcomes.
Target Audience
The primary customers are pharmaceutical companies and research institutions involved in preclinical drug discovery and development.
Features
- Microfluidic chips with integrated vascular networks to mimic human tissue microenvironment
- Software platform for designing and controlling complex experimental parameters
- Real-time monitoring of cellular responses and drug interactions
- Customizable chip designs to model various organ systems
- High-throughput screening capabilities for efficient drug candidate evaluation